Market sizing & epidemiology
A defensible epi-anchored sizing model the team can take to the board.
Shortlist it, send it over — we come back with the shape we'd actually recommend.
What market sizing & epidemiology actually is.
A defensible, epi-anchored sizing model the team can take to the board. Incidence, prevalence, treated population and line-of-therapy splits with sources and assumptions named on the row rather than buried in a tab.
Built for asset and portfolio teams where the gap between the forecast number and a defensible sizing is the difference between leadership belief and outside scrutiny.
- Written sizing report with method, sources and assumptions
- Working sizing model with row-level provenance
- Segmented cuts by line of therapy and sub-population
- Sensitivity ranges with the conditions that bound each
- Live sizing portal for leadership and finance
Add the pieces you'd want and we'll build a shortlist you can review, reorder and send over. No pricing wall, no commitment — we come back with what we'd actually recommend, including anything you don't need.
Approach, modules, delivery.
Move through the tabs to see how the work runs, what it's made of and what lands at the end.
Inputs
- Published epidemiology and registry data per market
- Treatment guidelines and current-practice reads
- Pricing signal and treated-population estimates from analogous assets
Method
A scoped study that builds the epidemiology base from first principles - incidence, prevalence, diagnosed, eligible, treated, by line of therapy - then turns it into a sizing model with every input sourced and every assumption named. The output is a defensible number the team can take to the board and a live portal that exposes the funnel so the assumptions stay legible.
Assumptions
- Published epi is sufficient for the lead markets; we'll name the markets where it isn't and flag the local primary research needed.
- The team wants ranges with sources, not a single point estimate.
Limitations
- Where local registries are thin, the model uses triangulated estimates with explicit confidence bands.
- Sizing ≠ forecast - share, persistence and price are out of scope here.
Think this belongs in your scope?
Add it alongside anything else that fits, then send the shortlist over. We'll reply with the shape we'd recommend — sequence included, and the parts we think you can skip.
Build what comes next.
Whether you need growth, answers or capability, VISFO helps you move earlier and faster.